| 0.5113 -0.014 (-2.65%) | 10-30 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.68 | 1-year : | 0.8 |
| Resists | First : | 0.58 | Second : | 0.68 |
| Pivot price | 0.45  |
|||
| Supports | First : | 0.42 | Second : | 0.31 |
| MAs | MA(5) : | 0.5 |
MA(20) : | 0.44 |
| MA(100) : | 0.42 |
MA(250) : | 0.37 |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 76.5 |
D(3) : | 74.2 |
| RSI | RSI(14): 55.2 |
|||
| 52-week | High : | 0.74 | Low : | 0.18 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ CBIO ] has closed below upper band by 23.4%. Bollinger Bands are 42.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 0.58 - 0.58 | 0.58 - 0.59 |
| Low: | 0.52 - 0.52 | 0.52 - 0.52 |
| Close: | 0.52 - 0.53 | 0.53 - 0.53 |
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation. The company's protease engineering platform creates improved or novel molecules to treat diseases that result from dysregulation of the complement system. It develops CB 2782-PEG, a component 3 (C3) degrader for the treatment of dry age-related macular degeneration (dAMD); and CB 4332 for patients with deficiencies in complement factor I (CFI), including dAMD. The company also develops ProTUNE C3b/C4b degrader and ImmunoTUNE C3a/C5a degrader platforms designed to target other disorders of the complement or inflammatory pathways. It has a strategic research collaboration with Mosaic Biosciences, Inc.; and license and collaboration agreement with Biogen International GmbH. Catalyst Biosciences, Inc. was founded in 2002 and is headquartered in South San Francisco, California.
Mon, 30 Oct 2023
Catalyst Biosciences Announces Completion of Business Combination With Beijing Continent Pharmaceuticals and ... - GlobeNewswire
Mon, 04 Sep 2023
Bio & Healthcare Tech Investments & Thesis | a16z - Andreessen Horowitz
Wed, 23 Aug 2023
Is Catalyst Biosciences (CBIO) Significantly Overvalued? - Yahoo Finance
Wed, 26 Jul 2023
New CEOs for Catalyst, FibroGen, Pheon and Tae - BioCentury
Mon, 27 Feb 2023
GC Biopharma Signs Agreement with Catalyst Biosciences for the Acquisition of Rare Disease Pipeline in Hematology - PR Newswire
Tue, 27 Dec 2022
Catalyst Biosciences Completes First Steps in Reverse Merger Plan - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 38 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 27.7 (%) |
| Held by Institutions | 8.7 (%) |
| Shares Short | 34 (K) |
| Shares Short P.Month | 103 (K) |
| EPS | -20.71 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -11.78 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -41.3 % |
| Return on Equity (ttm) | -269.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.36 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -13 (M) |
| Levered Free Cash Flow | -3 (M) |
| PE Ratio | -0.03 |
| PEG Ratio | 0 |
| Price to Book value | -0.05 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.46 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|